Leukemia

In KOMET-007, ziftomenib plus 7+3 produced high responses and MRD-negativity rates in newly diagnosed NPM1-mutated or KMT2A-rearranged AML.

MRD responses appeared to be more favorable with the use of blinatumomab among pediatric patients with high-risk B-cell acute lymphoblastic leukemia.

A phase 1b/2 trial of azacitidine, venetoclax, and ivosidenib showed composite complete remissions and MRD negativity in newly diagnosed IDH1-mutated AML.

Findings from the ASC4FIRST trial show that asciminib is meeting high expectations as a frontline therapy in chronic myeloid leukemia in chronic phase.

Data from the CASSIOPEIA trial showed that more than half of patients with high-risk disease achieved 5-year disease-free survival with tisagenlecleucel.

Real-world data support prospective evaluation of a frontline venetoclax-based regimen in the second line and beyond.

More than 90% of patients achieved a composite complete response to azacitidine plus venetoclax and ivosidenib in a phase 1b/2 trial.

The nilotinib tablets may support patients who have difficulty swallowing while offering flexibility to take treatment with or without water.

Researchers have shown that mycophenolate mofetil accelerates neutrophil engraftment compared to methotrexate in cord blood transplantation.

Data from a phase 2 trial show that quizartinib plus omacetaxine mepesuccinate may better position patients to proceed to consolidative transplantation.

Investigators are assessing CLN-049 among patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome in a phase 1 study.

Data from the phase 1/2 ASTX727-07 study support the FDA approval of decitabine plus cedazuridine and venetoclax in this AML population.

The ASPHO Conference brings together the world’s leading experts in pediatric oncology and hematology, and this collection of posters detail new findings in care.

Investigators are on track to complete the phase 1b dose-escalation portion of the RAINIER trial in 2026.

New developments revealed regulatory milestones for bacterial therapeutic candidates and potential efficacy with vaccine-based approaches.

Hematologic oncologists discussed long-term survival data from the SEQUOIA and ALPINE trials exploring zanubrutinib in frontline and R/R CLL/SLL.

Data from the phase 1/2 CARDINAL trial support the breakthrough therapy designation for TERN-701 in this chronic myeloid leukemia population.

Orca-T has demonstrated clear benefits in reducing graft-vs-host disease among patients with hematologic malignancies, according to Wendy Stock, MD.

Although not yet mature, overall survival data trended in favor of pirtobrutinib plus venetoclax/rituximab in the phase 3 BRUIN CLL-322 trial.

Newer generations of BTK inhibitors may have fewer cardiac toxicities compared with earlier iterations, according to Nicole Lamanna, MD.

Acalabrutinib/venetoclax may offer less toxicity compared with other therapies in chronic lymphocytic leukemia, said Nicole Lamanna, MD.

No patients with frontline acute myeloid leukemia experienced cytokine release syndrome following treatment with mipletamig plus venetoclax/azacitidine.

Preliminary findings have shown an “unprecedented” result with blinatumomab in mixed phenotype acute leukemia, according to Ashkan Emadi, MD, PhD.

Data from the phase 3 Precision-T trial show improvements in overall survival and relapse-free survival with the use of Orca-T.